Biostrategenix

The FDA’s approach to inspections has changed dramatically since the pandemic. A new guidance document titled “Alternative Tools: Assessing Drug Manufacturing Facilities Identified in Pending Applications” came out on September 12, 2025. This document shows a radical alteration in regulatory oversight for pharmaceutical drug manufacturing.

Traditional on-site inspections proved not to be the only way that worked to assess facilities during COVID-19. The FDA created a 2-year old flexible, risk-based system that allows alternative assessment methods beyond in-person visits. Remote Regulatory Assessments (RRAs), trusted foreign regulatory partners’ information, and FDA remote subject-matter experts now support preapproval inspections. This guidance focuses solely on agency audits for pending applications, not postapproval surveillance or for-cause inspections.

The relationship between regulatory compliance and quality in pharmaceutical manufacturing makes this change vital. Manufacturers have always prioritized quality systems. Yet FDA inspection requirements need both quality and compliance proof. These new assessment tools can speed up approvals, especially for U.S.-based facilities under Executive Order 14293. Your success in this new regulatory world depends on understanding these alternative tools, regardless of your facility’s experience with FDA preapproval inspections.

How FDA’s Alternative Tools Are Reshaping Inspections

The FDA’s regulatory landscape for pharmaceutical inspections has seen remarkable changes over the last several years. Since 2020, and in response to the need for social distancing due to Covid, the FDA has moved away from traditional on-site inspections and embraced various alternative assessment tools. This change shows more than just a response to travel limits; it points to a fundamental rethinking of regulatory oversight in our digital world.

From On-Site to Remote: A Regulatory Rise

FDA inspections once meant teams of inspectors arriving at facilities with clipboards. Those days are becoming history. This change started as a necessity during travel restrictions but has become a strategic advantage for regulators and manufacturers alike.

The FDA now uses several assessment methods beyond traditional on-site inspections:

• Remote Regulatory Assessments (RRAs): These evaluations let FDA review records and conduct virtual interviews without physical presence

• Records requests under section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act: FDA can request records before or instead of certain inspections

• Remote Interactive Evaluations (RIEs): Real-time video assessments of facilities and processes

• Remote Subject Matter Expert support: Expert knowledge available regardless of location

These tools address a vital difference between quality and compliance in pharmaceutical manufacturing. Many manufacturers have strong quality systems but find it hard to show regulatory compliance. Alternative assessment methods help companies demonstrate compliance in multiple ways, which accelerates the approval process.

“The approaches described in this guidance may be used to support approval decisions when the agency cannot conduct a timely on-site preapproval inspection,” notes the FDA in their guidance document. This framework provides flexibility while maintaining strict oversight.

Executive Order 14293 and Domestic Manufacturing Goals

The White House issued Executive Order 14293 in April 2022 to strengthen America’s leadership in manufacturing pharmaceuticals and active pharmaceutical ingredients (APIs). This order shapes FDA’s facility assessment approach and sets clear priorities favoring domestic manufacturing.

The FDA must think about how approval decisions can promote resilient supply chains and domestic manufacturing of essential medicines under this order. U.S.-based facilities might get faster assessments through alternative tools when traditional inspections could delay approval.

Pharmaceutical manufacturers face new opportunities and challenges. Domestic facilities could benefit from quicker approvals through alternative assessment methods. The compliance standards remain high maybe even higher as these tools enable deeper examination of documentation and processes.

The FDA chooses the best alternative assessment approach for each situation based on risk assessment. Their decision depends on the facility’s compliance history, product complexity, and previous inspection records.

Manufacturers must understand both compliance requirements and FDA’s strategic priorities in this changing landscape. Alternative assessment tools represent more than just convenient options—they show a fundamental change in how regulators ensure safe, effective pharmaceuticals for the public.

Breakdown of Remote Assessment Tools and Their Use Cases

The FDA has expanded its toolkit beyond traditional in-person visits to review drug manufacturing facilities. These new approaches have changed how manufacturers get ready for regulatory review.

Mandatory Records Requests Under FDCA §704(a)(4)

The FDA can now review your facility’s paperwork without an in-person visit. Section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act lets the FDA ask for validation data, batch records, and deviation reports before or instead of an inspection ^[1]. This isn’t optional – saying no is against the law.

Facilities need to send documents electronically through FDA’s secure systems. The FDA expects responses in 15 business days, which extends to 30 days if translation is needed ^[2]. Manufacturers must keep their documentation well-organized and easy to find. Your paperwork skills will be put to the test!

Voluntary Remote Interactive Evaluations (RIEs)

RIEs are like video calls with the FDA. They use livestreaming, screen sharing, and online meetings to check your operations virtually ^[1]. While you can say no to an RIE, this might slow down decisions on pending applications.

The FDA might:

• Ask for documents and access to electronic systems

• Watch facilities and operations through livestreams

• Talk to the core team

• Review fixes from earlier inspections ^[3]

RIEs don’t result in Form FDA 483 that lists inspection findings. The FDA still shares written observations in a final meeting ^[4]. You have 15 business days to respond – just like regular inspections.

Remote SMEs in Preapproval and Prelicense Inspections

FDA inspectors sometimes need expert help. Remote Subject Matter Experts (SMEs) bring specialized knowledge without traveling ^[1]. These experts join inspection teams virtually to provide technical support.

The FDA asks facilities to confirm they’ll work with remote experts and support the needed technology ^[5]. Saying no won’t break any rules but might delay application decisions ^[2]. This matters when you’re racing competitors to market.

Collaborative Hybrid Inspections with Foreign Authorities

Regulatory teamwork has reached new levels. In hybrid inspections, one authority visits the site while others join remotely ^[6]. This makes good use of agreements with trusted international partners.

The first collaborative review happened in September 2023. The FDA led while regulators from Japan, Switzerland, UK, Israel, and Europe watched remotely ^[6]. Global manufacturers must be ready to answer questions from multiple agencies at once. This needs careful planning and coordination among compliance teams.

These tools show how compliance and quality are different. A facility might have great quality systems but struggle with regulatory compliance. Smart use of these new review methods helps manufacturers handle both aspects and might speed up approvals.

Strategic Readiness for Pharmaceutical and Biopharmaceutical Sites

Getting ready for FDA’s new alternative assessment methods needs a different mindset than traditional inspections. Your success depends on how well you prepare in three key areas. FDA inspections are entering a new phase with these alternate inspection methods. Ask us how Biostrategenix can help.

Facility Self-Audits and Documentation Preparedness

Self-audits protect you before any FDA evaluation takes place. A full self-examination of your facility and operations helps identify and fix compliance issues early. This hands-on strategy lets you spot potential problems before they become official observations.

Documentation is the life-blood of regulatory readiness. Detailed, accurate records of all procedures, from manufacturing to packaging and labeling show compliance with FDA guidelines. RRAs need organized documents in a logical, easy-to-navigate system that proves both compliance and competence.

A dedicated RRA SharePoint or secure portal with indexed, searchable PDFs should contain:

• Last three years of batch records and deviation files

• Validation/qualification reports and SOPs

• Site-master diagrams and quality-system descriptions

The format carries significant weight and FDA can ask for English or certified translations, and all scans must be legible and searchable.

Technology Readiness: Secure Streaming and File Sharing

Your tech setup must meet FDA’s standards to observe and evaluate properly. Poor video quality or network security issues might force FDA to stop the RRA and switch to other oversight actions. Make sure your facility supports all technical requirements before agreeing to a voluntary RRA.

FDA typically checks your readiness by:

• Screening for hardware and software configurations

• Testing internet connection, bandwidth, and signal strength

• Looking at time zone differences and translation needs

• Setting up secure information sharing methods

Video quality plays a crucial role in livestream capabilities. FDA needs a strong remote connection to review, observe, and evaluate your processes effectively. FDA’s approved software systems must be used to maintain security.

Responding to FDA’s Written RRA Observations

FDA might hold a closeout meeting and provide written observations after an RRA. While no Form 483 gets issued, the stakes remain equally high.

You have 15 business days to respond, matching the timeline of traditional inspection findings. This window lets you show your steadfast dedication to compliance through a detailed reply.

Your responses should go beyond fixing specific issues. Take this chance to find and address similar weak points across your quality system. This all-encompassing approach shows FDA you see the difference between quick fixes and true quality and compliance commitment.

Balancing Regulatory Compliance and Product Quality

“FDA uses a risk-based approach to determine if alternative tools, including requesting records from manufacturers, remote interactive evaluations of facilities, and receiving information from foreign regulatory partners, may be used.” — Michael Kopcha, Director, FDA Office of Pharmaceutical Quality

FDA’s Risk-Based Framework for Tool Selection

The FDA uses a sophisticated risk-based model to choose assessment tools for your facility. Their team weighs multiple factors before deciding between an on-site inspection or an alternative method.

The FDA looks at several key elements:

1. Your facility’s compliance history and previous inspection results

2. Record of product recalls linked to your facility

3. Inherent risk of the drugs you manufacture (dosage form, route of administration, etc.)

4. Whether a trusted foreign regulatory partner has inspected your facility ^[7]

The data shows over 90% of inspections find facilities have acceptable CGMP compliance ^[8]. The FDA might prioritize facilities based on risk factors such as sterile products or narrow therapeutic index drugs ^[9].

If you are due for an surveillance or a compliance inspection, Biostrategenix can help. FDA’s practices are evolving. Let’s get ahead of mere audit prep and proactively become inspection ready.

Case Study: Quality System Success, Compliance Failure

Ranbaxy Laboratories’ story serves as a cautionary tale. This major global generic pharmaceutical company faced multiple FDA import bans and substantial penalties between 2008-2014 ^[10]. Their case shows how a company can have quality systems yet still fail at regulatory compliance.

Ranbaxy had to rebuild from the ground up. The company upgraded facilities, implemented better quality control systems, and trained staff extensively ^[10]. The lesson became clear – quality systems alone won’t guarantee compliance success.

Why Quality Alone Is Not Enough for Regulatory Approval

The sort of thing I love about this topic: focusing only on quality without addressing compliance creates regulatory bottlenecks and legal risks ^[11]. A rigid “check-the-box” mentality emerges when companies fixate solely on compliance, which doesn’t serve patients well ^[11].

Successful manufacturers see compliance as complementary to quality, not an added expense ^[12]. Both elements ensure conformance to defined requirements. Quality addresses patient and market expectations, while compliance meets regulatory standards that ensure baseline performance ^[12].

FDA’s alternative assessment tools give manufacturers options to showcase both quality and compliance. This approach could speed up approval timelines without compromising standards.

Implications for Global and Domestic Manufacturing Networks

Recent changes in FDA’s assessment methods have revolutionized the global pharmaceutical world. My work with domestic and foreign manufacturers has given me firsthand experience of how these changes affect facility networks worldwide.

FDA’s Prioritization of U.S. Facilities Under EO 14293

Executive Order 14293, signed in May 2025, creates a clear path to boost American pharmaceutical manufacturing. The numbers tell a compelling story – over half of pharmaceuticals distributed in the U.S. come from overseas facilities. Only 11% of API manufacturers operate domestically ^[13]. The FDA started its PreCheck program to tackle this imbalance. This program offers a two-phase approach with better communication during facility design, construction, and pre-production ^[13]. You can think of it as the TSA PreCheck for drug manufacturers – it speeds things up for qualified companies!

Increased Oversight of Foreign Sites via RRAs and Inspections

Foreign facilities now face stricter scrutiny. The FDA has expanded unannounced inspections at overseas manufacturers ^[14]. Commissioner Makary ended what he called a “double standard” where foreign companies got advance notice while American ones didn’t ^[14]. The results speak volumes – FDA found serious problems at foreign sites more than twice as often as domestic inspections, despite the advance warning ^[14].

Impact on Agency Audits and Approval Timelines

FDA’s new AI tool, Elsa, has become a key player in this transformation. This tool helps speed up clinical protocol reviews and identifies high-priority inspection targets ^[15]. Drug approval decisions now take less time than the previous 6-10 month timeline ^[15]. Elsa handles reading, writing, and summarizing tasks while keeping all information secure within the agency ^[15].

Conclusion

The pharmaceutical regulatory world has changed dramatically right in front of us. FDA’s new alternative assessment methods now offer much-needed flexibility while you retain control of rigorous oversight standards. These changes help both regulators and manufacturers by making processes simpler without risking product safety.

Quality systems alone won’t guarantee successful inspections. You need to master both quality and compliance – excellent internal processes paired with clear regulatory adherence. Many companies do well in one area but struggle with the other. These alternative tools give manufacturers new ways to show their strengths in both areas.

FDA inspections are entering a new phase with these alternate tools. Ask us how Biostrategenix can help. Companies that accept new ideas and arm themselves with proper documentation, technology readiness, and complete response strategies will definitely guide through these changes better than those stuck with old inspection methods.

These changes reach way beyond the reach and influence of individual facilities. Executive Order 14293 highlights the special importance of domestic manufacturing, though foreign facilities remain vital to our supply chain. Knowing how to use these assessment tools is crucial whatever your manufacturing location.

These changes highlight a key truth – regulatory compliance isn’t just about checking boxes. It shows your steadfast dedication to quality through multiple channels. Your success in this new pharmaceutical inspection era depends on how well you showcase both quality systems and regulatory compliance – whether during an RRA, hybrid inspection, or traditional on-site visit. Modern pharmaceutical manufacturing oversight looks nothing like the clipboard-wielding inspectors of yesterday!

Key Takeaways

The FDA has revolutionized pharmaceutical inspections with new alternative assessment tools that offer flexibility while maintaining rigorous oversight standards for drug manufacturers.

• FDA now uses Remote Regulatory Assessments (RRAs), records requests, and hybrid inspections instead of relying solely on traditional on-site visits for preapproval evaluations.

• Executive Order 14293 prioritizes U.S. manufacturing facilities through expedited PreCheck programs, while foreign sites face increased scrutiny and unannounced inspections.

• Quality systems alone don’t guarantee regulatory success—manufacturers must demonstrate both excellent internal processes and clear regulatory compliance documentation.

• Facilities need technology readiness with secure streaming capabilities, organized digital documentation, and 15-day response protocols for FDA’s written observations.

• Risk-based assessment selection considers facility compliance history, product complexity, and previous inspection results to determine the most appropriate evaluation method.

These alternative tools represent more than pandemic adaptations—they’re permanent changes that require manufacturers to excel at both quality management and regulatory compliance demonstration. Success depends on proactive preparation, comprehensive documentation systems, and understanding that compliance isn’t just box-checking but showcasing commitment to patient safety through multiple channels.

References

[1] – https://www.fdamap.com/blog/fda-guidance-embraces-hybrid-inspection-model-for-gmp-facilities/
[2] – https://www.raps.org/news-and-articles/news-articles/2025/9/fda-finalizes-guidance-on-alternative-inspection-t
[3] – https://www.raps.org/news-and-articles/news-articles/2023/10/fda-addresses-use-of-remote-interactive-evaluation
[4] – https://www.ropesgray.com/en/insights/alerts/2025/07/fda-finalizes-guidance-on-remote-regulatory-assessments-but-how-will-they-support
[5] – https://www.fda.gov/media/172290/download
[6] – https://caiready.com/life-sciences/blog/the-future-of-fda-regulatory-inspections/
[7] – https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-basics/fdas-risk-based-approach-inspections
[8] – https://www.fda.gov/drugs/guidance-compliance-regulatory-information/pharmaceutical-inspections-and-compliance
[9] – https://www.fda.gov/media/116004/download
[10] – https://inotek.co.in/blogs/impact-of-fda-inspections-on-pharma-plant-operations?slug=impact-of-fda-inspections-on-pharma-plant-operations
[11] – https://pharmatechassociates.com/blog/quality-vs-compliance-in-pharma-understanding-the-difference/
[12] – https://compliancearchitects.com/quality-versus-compliance-fda-regulated/
[13] – https://www.fda.gov/news-events/press-announcements/fda-announces-new-fda-precheck-program-boost-us-drug-manufacturing
[14] – https://www.fda.gov/news-events/press-announcements/fda-announces-expanded-use-unannounced-inspections-foreign-manufacturing-facilities
[15] – https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-launches-ai-tool-reduce-time-taken-scientific-reviews-2025-06-02/